Cabaletta Bio to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

On May 27, 2021, Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies, announced that CEO Steven Nichtberger will participate in a fireside chat at the Jefferies Healthcare Conference on June 3, 2021, at 4:30 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for 90 days post-event. Cabaletta's lead candidate, DSG3-CAART, is in a Phase 1 trial for treating mucosal pemphigus vulgaris, with Fast Track Designation from the FDA since May 2020.

PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m. ET.

A live webcast of the fireside chat will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

FAQ

What is the date and time of the fireside chat for CABA at the Jefferies Healthcare Conference?

The fireside chat for Cabaletta Bio (CABA) is scheduled for June 3, 2021, at 4:30 p.m. ET.

Where can I watch the CABA fireside chat live?

The live webcast of the CABA fireside chat will be available on Cabaletta Bio’s website under the News and Events section.

What is DSG3-CAART, related to CABA?

DSG3-CAART is Cabaletta Bio's lead product candidate in a Phase 1 trial for potentially treating mucosal pemphigus vulgaris.

What designation has the FDA granted to DSG3-CAART?

The FDA granted Fast Track Designation to DSG3-CAART in May 2020.

How long will the webcast of the CABA fireside chat be available for replay?

The replay of the CABA fireside chat will be available on the company’s website for 90 days after the event.